Davocet & Darvon Pulled From Market After Study Correlates Use With Deadly Heart Problems


On November 19, 2010 the FDA ordered the popular painkillers Darvocet & Darvon to be pulled from the market.

The decision to pull Darvocet & Darvon came after exhaustive studies and feedback from panels assembled by the FDA to evaluate the drugs safety. The results followed careful evaluation of advisory panel findings and data from scientific studies that concluded that the drugs should be pulled from the market because of the strong correlation to QT internal abnormalities in the heart.

Specifically, electrocardiography data demonstrated that even healthy patients developed abnormal heart rhythms after using Darvocet and Darvon (propoxyphene) as intended with the dosages recommended by the manufacturer.

Though these drugs were approved for treatment of pain more than 50 years ago, there has been widespread requests to have the drugs removed from the market as more painkillers have become available that have minimal side-effects.

The legal rights of for those who were injured or killed

Given the extensive history of use of Darvocet and Darvon, it is extremely likely that the manufacturer Xanodyne Pharmaceuticals, Inc. had knowledge of the dangers of the heart problems associated with these drugs– yet never warned the public or took action to remove them from the market prior to this recent FDA action.

If you have a loved one who suffered an injury or death following the use of Darvocet or Darvon, you may have legal rights for damages against the drug manufacturer.  Currently, we are evaluating cases involving the following complications:

  • Irregular heart rhythms
  • Bradycardia
  • Stroke
  • Techycardia
  • Heart attack
  • Heart failure
  • Blockage in the heart
  • Death

Though Darvocet and Darvon lawsuits are in the early stages, you may wish to talk with a drug lawyer to discuss your potential legal rights.

As always, we offer you the opportunity to speak to a lawyer for a free evaluation of your circumstance. (888) 424-5757


Xanodyne agrees to withdraw propoxyphene from the U.S. market, November 19, 2010 FDA


Client Reviews

He did a tremendous job on our case and I can see why he's earned the praise he has from clients and peers.